EXECUTIVE ENGAGEMENTS
POOL
3211
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
578
Interactions with Platform & by Email
PARTICIPANTS
96
Unique # Participated
VALIDATIONS
28
Responses Validated*
COMPANIES
15
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
105
PAGES
150
EDITION
8
PRICE
USD 4950
CODE
MCP10788
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Global Brain Tumor Therapeutics Market to Reach $3.1 Billion by 2026
Amid the COVID-19 crisis, the global market for Brain Tumor Therapeutics estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$3.1 Billion by 2026, growing at a CAGR of 9.6% over the analysis period. Cell-Based Products, one of the segments analyzed in the report, is projected to record a 10.1% CAGR and reach US$2.3 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Acellular Products segment is readjusted to a revised 8.6% CAGR for the next 7-year period.
The U.S. Market is Estimated at $583.2 Million in 2021, While China is Forecast to Reach $532.4 Million by 2026
The Brain Tumor Therapeutics market in the U.S. is estimated at US$583.2 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$532.4 Million by the year 2026 trailing a CAGR of 9% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.9% and 7.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.
SELECT PLAYERS
AstraZeneca PLC; Bristol-Myers Squibb Company; DelMar Pharmaceuticals, Inc.; Eisai Co., Ltd.; Emcure Pharmaceuticals Pvt., Ltd.; F. Hoffmann-La Roche AG; Fresenius Kabi Oncology Ltd.; ImmunoCellular Therapeutics Ltd.; iTeos Therapeutics SA; Kazia Therapeutics Ltd.; Merck & Co., Inc.; Moleculin Biotech, Inc.; Navinta LLC; NextSource Biotechnology, LLC; Northwest Biotherapeutics, Inc.; Novartis International AG; NovoCure Ltd. (Channel Islands); Tocagen, Inc.; United Technologies Corporation (UTC)
SEGMENTS
» Product (Cell-Based Products, Acellular Products) » Therapy (Cell Therapy, Tissue Engineering, Immunotherapy, Gene Therapy)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Brain Tumor Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Brain Tumor Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Brain Tumor Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Cell-Based Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cell-Based Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cell-Based Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Acellular Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Acellular Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Acellular Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Tissue Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Brain Tumor Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Brain Tumor Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Brain Tumor Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Brain Tumor Therapeutics by Product - Cell-Based Products and Acellular Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Brain Tumor Therapeutics by Product - Percentage Breakdown of Value Sales for Cell-Based Products and Acellular Products for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Brain Tumor Therapeutics by Therapy - Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Brain Tumor Therapeutics by Therapy - Percentage Breakdown of Value Sales for Cell Therapy, Tissue Engineering, Immunotherapy and Gene Therapy for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 15 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com